[Genetic analysis in prostate cancer].
Following mile stone discoveries of ETS family-associated gene fusion and splicing variant of androgen receptor, next generation sequencing (NGS) has been rapidly introduced to prostate cancer research and already provided several important information on genomic alteration of the disease. Those mutational landscapes demonstrated the generally lower mutation rate through treatment-naive to lethal castration resistant stages compared to other major malignant diseases and implicated distinct pathomechanisms with regard to the presence of ETS family-associated gene fusion. Future direction of prostate cancer genomics using NGS will pursue the path up to the elucidation of more specific biological characteristics of the disease such as tumor heterogeneity and preference of bone metastasis, whereas another trend will lead this technology to broader application for a larger, unbiased patient population.